|
Price: $9.5100
$-0.12 
-1.246%
|
| Day's High:
| $9.59
| Week Perf:
| -3.35 %
|
| Day's Low: |
$ 9.29 |
30 Day Perf: |
22.39 % |
| Volume (M): |
872 |
52 Wk High: |
$ 11.49 |
| Volume (M$): |
$ 8,288 |
52 Wk Avg: |
$8.64 |
| Open: |
$9.51 |
52 Wk Low: |
$6.51 |
|
|
| Market Capitalization (Millions $) |
542 |
| Shares
Outstanding (Millions) |
57 |
| Employees |
130 |
| Revenues (TTM) (Millions $) |
185 |
| Net Income (TTM) (Millions $) |
-63 |
| Cash Flow (TTM) (Millions $) |
-15 |
| Capital Exp. (TTM) (Millions $) |
1 |
Evolus Inc
Evolus Inc is a biotechnology and aesthetics company that is headquartered in Newport Beach, California. The company specializes in the development and commercialization of medical products that improve the appearance and well-being of individuals. Evolus Inc was founded in 2012 by a team of healthcare professionals and biotech industry veterans who had a vision of transforming the aesthetic industry through innovation.
One of Evolus Inc's flagship products is Jeuveau, a prescription medicine that is used to improve the appearance of frown lines between the eyebrows in adults. Jeuveau is a botulinum toxin type A injectable that works by blocking the nerve signals that cause muscles to contract. The treatment temporarily relaxes the muscles, thereby smoothing out the wrinkles and lines on the face. Jeuveau was approved by the US Food and Drug Administration (FDA) in 2019 and is the first new botulinum toxin approved for aesthetics in over a decade.
Evolus Inc is also actively engaged in the research and development of new medical products for aesthetics and other therapeutic areas. The company has a robust pipeline of programs in various stages of development, including biosimilars, topical formulations, and neurotoxins. Evolus Inc has a strong focus on using advanced technologies to improve the safety, efficacy, and convenience of its products.
In addition to its core operations, Evolus Inc is committed to advancing the aesthetics industry through education and collaboration. The company partners with healthcare providers and industry experts to advance best practices and promote patient safety. It also supports research initiatives that seek to better understand the science behind aging and aesthetics.
Evolus Inc is led by a team of seasoned executives with extensive experience in the biotech and aesthetics industries. The company is publicly traded on the NASDAQ stock exchange and has a global reach through its partnerships with distributors and healthcare providers. Evolus Inc has earned recognition for its innovative products, commitment to quality, and dedication to improving patient outcomes.
Company Address: 520 Newport Center Drive Suite 1200 Newport Beach 92660 CA
Company Phone Number: 284-4555 Stock Exchange / Ticker: NASDAQ EOLS
| EOLS is expected to report next financial results on March 07, 2024. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals Inc, a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections, recently announced its financial results for the July to September 30, 2023, period. During this period, the company reported an increase in losses, which expanded from $1.27 per share a year prior to $1.32 per share. However, it is worth noting that the earnings per share (EPS) improved from -$1.86 in the preceding reporting period.
The revenue for the same period decreased by 6.817% to $18.93 million compared to $20.32 million in the previous reporting period. While sequentially, the revenue advanced slightly by 0.212% from $18.89 million. This decline in revenue could raise concerns, as it may indicate slowing demand for Enanta Pharmaceuticals Inc's products.
|
|
Procyon Corporation
Based on the financial time-frame ending September 30, 2023, Procyon Corporation has experienced significant declines and challenges, leading to a bearish outlook for the company. Depleting orders have played a crucial role in the losses incurred during this period.
The revenue for Procyon Corporation fell by -0.221% to $1.17 million compared to the previous reporting season, where revenue decreased by -2.42% from $1.20 million. This downward trend indicates a constant struggle for the company to maintain a steady revenue stream. It is clear that Procyon Corporation has been facing difficulties in generating consistent income.
|
|
China Health Industries Holdings Inc
China Health Industries Holdings Inc (CHHE) recently announced its financial results for the fiscal period ending September 30, 2023. These results demonstrate the company's ability to achieve top-line growth despite industry-wide revenue reductions. Additionally, CHHE's inventories have declined, indicating potential future demand. This article will outline the facts and set the current financial results into context.
Financial Results Overview:
For the fiscal period ending September 30, 2023, CHHE reported a zero gain of $0.00 per share, compared to a loss of $0.01 per share during the same period a year ago. Sequentially, CHHE improved from a loss of $0.01 per share in the previous quarter. This indicates progress in generating profits and more favorable financial performance.
|
|
Acer Therapeutics Inc
The stock performance of a company plays a vital role in determining its overall financial health. Acer Therapeutics Inc, a major player in the pharmaceutical preparations industry, has experienced a decline in its stock price over the past week, negatively impacting its year-to-date performance. This article aims to provide an overview of the recent trends seen in Acer Therapeutics Inc's stock performance, along with insights into the company's financial records and future expectations.
Stock Performance
Over the past week, Acer Therapeutics Inc's stock has experienced a decline, although the exact percentage decrease is undisclosed in the provided information. This downtrend has brought the company's year-to-date performance to a staggering -74.81%. Consequently, investors may have concerns about the company's financial stability, prompting a closer examination of its financial records.
|
|
Baudax Bio Inc
Baudax Bio Inc, a pharmaceutical company listed on the NASDAQ, recently released its financial results for the July to September 2023 period. The company demonstrated significant improvements in its loss per share and earnings per share compared to the previous year and the previous quarter. Despite revenue remaining unchanged, Baudax Bio Inc reported a substantial decrease in its net shortfall. This article aims to outline the facts and interpret these financial results.
1. Improving Financial Performance:
For the July to September 2023 period, Baudax Bio Inc managed to decrease its loss per share from $-2.47 to $-0.30 when compared to the same quarter last year, showcasing a remarkable improvement. Moreover, earnings per share saw significant growth from $-1.51 in the previous quarter to the current quarter.
|
| Per Share |
Current |
| Earnings (TTM) |
-1.11 $ |
| Revenues (TTM) |
3.24 $
|
| Cash Flow (TTM) |
- |
| Cash |
0.68 $
|
| Book Value |
-
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.11 $
|
| Revenues (TTM) |
3.24 $ |
| Cash Flow (TTM) |
- |
| Cash |
0.68 $
|
| Book Value |
- |
| Dividend (TTM) |
0 $ |
|
|
|
|
